A clinical trial using donated eye tissue could offer new hope for people with sight problems, reports a new study. The findings of the study are published in the journal STEM CELLS Translational Medicine.
Doctors made the world-first step by carrying out a clinical trial using stem cells from donors to create tissue that was transplanted into patients with the condition that causes blindness.
Regenerating Eyes Using Stem Cells from Hair
A young scientist has used stem cells from hair follicles to treat eye surface disease has been named the winner of the Young Investigator Award by the journal Stem Cells .
Advertisement
‘Clinical trial using donated eye tissue could benefit people with sight problems and help restore the surface of the eye, reveals a new study.’
Read More..
Tweet it Now
Read More..
Researchers say the trial offers clues about how eye tissue loss could be repaired using stem cells from organ donors. It also sheds light on the causes of sight disorders.
The trial focused on limbal stem cell deficiency (LSCD), which can result from damage to the eye from chemicals or heat, or be caused by a disease called aniridia. It leads to scarring and severe vision loss in both eyes as well as chronic pain and redness.
![Aniridia]( "Aniridia")
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is associated with glaucoma, cataract, keratopathy and other eye problems.
LSCD is a significant cause of sight loss - especially in countries where resources and services are limited - but it does not typically respond to standard treatments.
To carry out the trial, researchers - led by the University of Edinburgh and the Scottish National Blood Transfusion Service - isolated stem cells in the eye's protective layer, known as the cornea.
A normal healthy cornea is transparent, but becomes scarred and opaque when specialized stem cells are lost in LSCD.
These cornea samples were taken from people who had donated their eyes after death.
The team then grew the stem cells - which have the unique ability to transform into other cell types - into tissue ready to be transplanted.
Sixteen patients were split into two groups with both given eye drops and medicines to suppress their immune system to reduce transplant rejection. One group was also given the stem cells.
This is the first time that stem cells have been used in this way in a randomized clinical trial - the gold standard scientific method for testing a new treatment.
Patients who had received the stem cells showed significant repair of their eyes' ocular surface - the outermost layer - over 18 months, which was not seen in those who did not receive the treatment.
Both the stem cell group and the control group showed improvements in vision, which researchers say warrants further investigation a larger trial.
Scientists have hailed the step as a landmark for cell-based surgery. They say it shows promise for repairing the eye's surface, paving the way for similar donor trials to be planned.
The team suggest that the immune system could play a driving role in some forms of LSCD, but caution that more research is needed.
The project was funded by UK Stem Cell Foundation, Scottish Enterprise and the Chief Scientist Office, part of Scottish Government Health Directorates.
Baljean Dhillon, Professor of Clinical Ophthalmology at the University of Edinburgh's Centre for Clinical Brain Sciences, who led the study, said: "The findings from this small study are very promising and show the potential for safe stem cell eye surgery as well as improvements in eye repair.
"Our next steps are to better understand how stem cells could promote tissue repair for diseases that are extremely hard to treat and if, and how, they could help to restore vision."
Marc Turner, Medical Director of the Scottish National Blood Transfusion Service and Professor of Cellular Therapy at the University of Edinburgh said: "Clinical studies such as these help us to understand how complex new cellular therapies may be able to complement existing medical approaches in restoring function to damaged tissues and organs."
Source: Eurekalert
Aniridia
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is associated with glaucoma, cataract, keratopathy and other eye problems.
Advertisement
LSCD is a significant cause of sight loss - especially in countries where resources and services are limited - but it does not typically respond to standard treatments.
To carry out the trial, researchers - led by the University of Edinburgh and the Scottish National Blood Transfusion Service - isolated stem cells in the eye's protective layer, known as the cornea.
A normal healthy cornea is transparent, but becomes scarred and opaque when specialized stem cells are lost in LSCD.
These cornea samples were taken from people who had donated their eyes after death.
The team then grew the stem cells - which have the unique ability to transform into other cell types - into tissue ready to be transplanted.
Sixteen patients were split into two groups with both given eye drops and medicines to suppress their immune system to reduce transplant rejection. One group was also given the stem cells.
This is the first time that stem cells have been used in this way in a randomized clinical trial - the gold standard scientific method for testing a new treatment.
Patients who had received the stem cells showed significant repair of their eyes' ocular surface - the outermost layer - over 18 months, which was not seen in those who did not receive the treatment.
Both the stem cell group and the control group showed improvements in vision, which researchers say warrants further investigation a larger trial.
Scientists have hailed the step as a landmark for cell-based surgery. They say it shows promise for repairing the eye's surface, paving the way for similar donor trials to be planned.
The team suggest that the immune system could play a driving role in some forms of LSCD, but caution that more research is needed.
The project was funded by UK Stem Cell Foundation, Scottish Enterprise and the Chief Scientist Office, part of Scottish Government Health Directorates.
Baljean Dhillon, Professor of Clinical Ophthalmology at the University of Edinburgh's Centre for Clinical Brain Sciences, who led the study, said: "The findings from this small study are very promising and show the potential for safe stem cell eye surgery as well as improvements in eye repair.
"Our next steps are to better understand how stem cells could promote tissue repair for diseases that are extremely hard to treat and if, and how, they could help to restore vision."
Marc Turner, Medical Director of the Scottish National Blood Transfusion Service and Professor of Cellular Therapy at the University of Edinburgh said: "Clinical studies such as these help us to understand how complex new cellular therapies may be able to complement existing medical approaches in restoring function to damaged tissues and organs."
Source: Eurekalert
Potential Cure for Aniridia Developed
The potential cure for aniridia, a rare eye disease that limits vision in humans, has now been developed by a team of Canadian scientists
Advertisement
 Research Suggests Nonsense Suppression Drug Restores Function in a Mouse Model of AniridiaCongenital aniridia is a condition that causes improper development of eye structures as well as abnormalities in the brain and pancreas. | Advertisement
|
Advertisement
Recommended Reading
Latest Clinical Trials News
The common non-viral sexually transmitted infection (STI) caused by Trichomonas vaginalis can be universally screened with a help of a finger-prick test.
What is the new trial treatment for prostate cancer? The addition of enzalutamide to the standard of care improved survival of metastatic prostate cancer patients.
In women with cervical cancer, whole genome sequencing results revealed new potential targets for drug development.
Is there a new way to treat lymphedema? Yes, swelling due to damaged lymphatic vessels can be treated using nanoparticles that can travel through the lymphatic vessels.
Early and late Chronic Traumatic Encephalopathy (CTE) disease processes in the post-mortem brains were similar in some ways but dramatically different in others.